Ocera Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

OCRX 2.78 +0.06 (2.21%)
price chart
Ocera Therapeutics Inc (OCRX) Earns "Sell" Rating from Zacks Investment Research
Ocera Therapeutics Inc logo Zacks Investment Research reaffirmed their sell rating on shares of Ocera Therapeutics Inc (NASDAQ:OCRX) in a research note issued to investors on Sunday morning, AnalystRatings.Net reports. According to Zacks, “Ocera ...
Ocera Therapeutics' (OCRX) Sell Rating Reaffirmed at Zacks Investment ...  Zolmax
Ocera Therapeutics Inc (OCRX) Given Sell Rating at Zacks Investment Research
Ocera Therapeutics logo Ocera Therapeutics Inc (NASDAQ:OCRX)'s stock had its “sell” rating reissued by Zacks Investment Research in a report issued on Sunday, Analyst Ratings Network.
Ocera Therapeutics Inc (OCRX) Receives "Sell" Rating from Zacks ...  IRA Market Report
Zacks Investment Research Reaffirms "Sell" Rating for Ocera ...  Corvus Business Newswire
Ocera Therapeutics Inc (OCRX) Upgraded at Zacks Investment Research
Ocera Therapeutics Inc logo Zacks Investment Research upgraded shares of Ocera Therapeutics Inc (NASDAQ:OCRX) from a sell rating to a hold rating in a research report sent to investors on Sunday, MarketBeat.
Zacks Investment Research Upgrades Ocera Therapeutics Inc (OCRX) to " ...  Corvus Business Newswire
Latest Analysts Reports On Ocera Therapeutics, Inc. (OCRX)
Recently stock market analysts have updated their consensus ratings on shares of Ocera Therapeutics, Inc. (OCRX). The latest broker reports which have been released state 1 analyst has a rating of “buy”, 2 analysts “outperform”, 0 analysts “hold”, 0 ...
Zacks: Ocera Therapeutics Inc (NASDAQ:OCRX) Given $11.50 Consensus Target ...  Financial Market News
Ocera (formerly Tranzyme) extends cash runway with $20M debt facility
Drug developer Ocera Therapeutics, Inc. (Nasdaq: OCRX) could borrow up to $20 million, extending the company's cash runway into at least mid-2017.
Ocera Therapeutics Inc (OCRX) Lowered to "Hold" at Zacks Investment Research
Ocera Therapeutics Inc logo Zacks Investment Research cut shares of Ocera Therapeutics Inc (NASDAQ:OCRX) from a buy rating to a hold rating in a research note published on Thursday morning, AnalystRatings.
Ocera Therapeutics Inc (OCRX) Insider Gaurav Aggarwal Purchases 10000 Shares
Ocera Therapeutics logo Ocera Therapeutics Inc (NASDAQ:OCRX) insider Gaurav Aggarwal acquired 10,000 shares of Ocera Therapeutics stock in a transaction dated Friday, January 15th.
Ocera Therapeutics, Inc. (OCRX) Files Form 4 Insider Buying : Michael Byrnes ...  The Daily Rover
Ocera Therapeutics Finally Ready To Reward Investors
... Ocera has had a rough 2014. Investors unfamiliar with the company would probably look at the stock chart and move on to the next assuming that something catastrophic had occurred to warrant such a steep price decline.
Linda S. Grais Purchases 10000 Shares of Ocera Therapeutics Inc (OCRX) Stock
Ocera Therapeutics logo Ocera Therapeutics Inc (NASDAQ:OCRX) CEO Linda S. Grais acquired 10,000 shares of Ocera Therapeutics stock in a transaction dated Friday, January 22nd.
Will Ocera Therapeutics Inc Go Down Anytime Soon?
The stock of Ocera Therapeutics Inc (NASDAQ:OCRX) is a huge mover today! The stock increased 4.40% or $0.11 on February 9, hitting $2.61.